Use of varicella vaccines to prevent herpes zoster in older individuals

Levin, Myron J.

doi:10.1007/978-3-7091-6259-0_16

Cited by 26 publications

(27 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These trials have demonstrated a boost of CMI to VZV safely in most elderly subjects when live attenuated vaccines, with higher potency than in varicella prevention, were used. While no firm conclusions can be drawn, there were encouraging suggestions of reduced occurrence and severity of zoster (91).…”

Section: Controversies Regarding Varicella Vaccinementioning

confidence: 99%

Preventing Varicella-Zoster Disease

2005

View full text Add to dashboard Cite

Varicella-zoster virus (VZV), the cause of chickenpox and shingles, is a pathogen in retreat following the introduction of mass vaccination in the United States in 1995. The live attenuated Oka vaccine, which is safe and immunogenic, gives good protection against both varicella and zoster in the short to medium term. It has undoubtedly been highly effective to date in reducing all forms of varicella, especially severe disease. However, the huge pool of latent wild-type virus in the population represents a continuing threat. Both the biology and the epidemiology of VZV disease suggest that new vaccination strategies will be required over time

show abstract

Section: Controversies Regarding Varicella Vaccinementioning

confidence: 99%

Preventing Varicella-Zoster Disease

2005

View full text Add to dashboard Cite

show abstract

“…Incidence HZ se zvyšuje s narůstajícím věkem pacienta (od 50 let výše) (4,5). Pravděpodobnost komplikací narůstá s věkem.…”

unclassified

The Evidence of Annual Occurrence of Varicella Zoster Virus (Vzv) in Temper Climate of Czech Republic

Boštíková¹,

Salavec²,

Sleha³

et al. 2018

MMSL

View full text Add to dashboard Cite

“…Subsequent studies have demonstrated that Oka-derived VZV vaccines can elicit a significant increase in VZV-CMI in immunocompetent older adults [32,[37][38][39] and can reduce the incidence and severity of HZ in recipients of bone marrow allografts [40,41]. These observations led us to hypothesize that immunization of older adults with live attenuated Oka VZV vaccine would boost their waning VZV-CMI and thereby provide protection against HZ and PHN [21,31,42,43]. The Shingles Prevention Study (SPS), Department of Veterans Affairs Cooperative Study #403, was initiated to test this hypothesis by determining whether vaccination with an investigational live attenuated Oka/Merck VZV vaccine would decrease the incidence and/or severity of HZ and PHN in immunocompetent adults у60 years of age.…”

mentioning

confidence: 99%

Vaccination against Herpes Zoster and Postherpetic Neuralgia

Oxman¹,

Levin²

2008

J INFECT DIS

160

100

View full text Add to dashboard Cite

Background. Herpes zoster (HZ) and postherpetic neuralgia (PHN) cause significant morbidity in older adults. The incidence and severity of HZ and PHN increase with age in association with an age-related decline in varicellazoster virus (VZV)-specific cell-mediated immunity (VZV-CMI). VZV vaccines can boost VZV-CMI. Therefore, we tested the hypothesis that VZV vaccination would protect older adults against HZ and PHN.Methods. We enrolled 38,546 adults у60 years of age in a randomized, double-blind, placebo-controlled trial of an investigational HZ vaccine and actively followed subjects for the development of HZ. The primary end point was the burden of illness due to HZ (HZ BOI), a composite measure of the incidence, severity, and duration of pain and discomfort caused by HZ. The secondary end point was the incidence of PHN.Results. Subject retention was 195%. HZ vaccine reduced the HZ BOI by 61.1% (95% confidence interval [CI], 51.1%-69.1%;) and reduced the incidence of PHN by 66.5% (95% CI, 47.5%-79.2%; ). The P ! .001 P ! .001 incidence of HZ was also reduced by 51.3% (95% CI, 44.2%-57.6%;). HZ vaccine was well tolerated; P ! .001 injection site reactions were generally mild. HZ vaccine neither caused nor induced HZ.Conclusion. The Shingles Prevention Study demonstrated that HZ vaccine significantly reduced the morbidity due to HZ and PHN in older adults.

show abstract

Use of varicella vaccines to prevent herpes zoster in older individuals

Cited by 26 publications

References 36 publications

Preventing Varicella-Zoster Disease

Preventing Varicella-Zoster Disease

The Evidence of Annual Occurrence of Varicella Zoster Virus (Vzv) in Temper Climate of Czech Republic

Vaccination against Herpes Zoster and Postherpetic Neuralgia

Contact Info

Product

Resources

About